Currently, HCC screening primarily relies on cross-sectional imaging such as magnetic resonance imaging (MRI), computed tomography (CT) scanning, ultrasonography (US), contrast-enhanced ultrasound (CEUS), and some tumor markers, particularly α-fetoprotein (AFP) (Frenette et al., 2019). Here, AFP is linked to hepatocellular carcinoma.